Annals of Allergy Asthma & Immunology最新文献

{"title":"From the pages of AllergyWatch","authors":"Stanley M. Fineman MD , Timothy Chow MD , Gerald B. Lee MD , Iris Otani MD","doi":"10.1016/j.anai.2025.02.005","DOIUrl":"10.1016/j.anai.2025.02.005","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 741-742"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-stop cough","authors":"Jonathan A. Bernstein MD","doi":"10.1016/j.anai.2025.01.005","DOIUrl":"10.1016/j.anai.2025.01.005","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 622-623"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What the clinician should know when ordering a mast cell tryptase test","authors":"Moïse Michel PharmD, PhD ,&nbsp;Delphine Giusti PharmD, PhD ,&nbsp;Caroline Klingebiel MD ,&nbsp;Bach-Nga Pham MD, PhD ,&nbsp;Joana Vitte MD, PhD","doi":"10.1016/j.anai.2025.03.003","DOIUrl":"10.1016/j.anai.2025.03.003","url":null,"abstract":"<div><div>Tryptase is currently the most specific mast cell biomarker available in clinical laboratories. Tryptase levels in the peripheral blood contribute to the diagnostic, prognostic, and therapeutic evaluation of the following 3 clinical categories: (1) immediate hypersensitivity reactions, including the life-threatening systemic form known as anaphylaxis; (2) clonal mast cell diseases and other myeloid malignancies, also as a biomarker for efficacy of chemotherapeutic agents targeting mast cell survival; and (3) hereditary α-tryptasemia, a genetic trait found in 4% to 8% of general population associated to increased risk of severe immediate hypersensitivity reactions. Rapidly evolving pathophysiology knowledge and management guidelines affect tryptase use in clinical practice, explaining the need for frequent updates. Such updates often lack context on the pathophysiology and methods regarding mast cells and tryptase, thus hampering the practicing clinician's ability to get the full picture from tryptase test results. Here, we provide the practicing physician with the 2025 state-of-the-art recommendations on tryptase use and interpretation in clinical practice, also exposing their basic, clinical, and technical foundations. Successive additions to mast cell and tryptase research are summarized and revisited in light of today's knowledge. The review sections are titled to reflect matter-of-fact questions arising in clinical practice. Currently unmet needs of tryptase use and selected lines of ongoing research expected to influence clinical practice in the near future are also presented.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 649-657"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of shared decision-making in determining challenge setting for nonsevere food protein-induced enterocolitis syndrome","authors":"Jason Sanders DO ,&nbsp;Alexandra E. Conway BA ,&nbsp;Navya Kartha DO ,&nbsp;Brinda Prasanna Kumar MD ,&nbsp;John Oppenheimer MD ,&nbsp;Marylee Verdi APRN, MSN ,&nbsp;Aikaterini Anagnostou MD, MSc, PhD ,&nbsp;Elissa M. Abrams MD, MPH ,&nbsp;Karen S. Hsu Blatman MD, MBA ,&nbsp;Matthew Greenhawt MD, MBA, MSc ,&nbsp;Marcus S. Shaker MD, MS","doi":"10.1016/j.anai.2025.01.022","DOIUrl":"10.1016/j.anai.2025.01.022","url":null,"abstract":"<div><h3>Background</h3><div>Food protein-induced enterocolitis syndrome (FPIES) affects approximately 0.5% of US children. Oral food challenges (OFCs) are frequently conducted to assess FPIES resolution in an observed setting, given the risk of severe reactions. However, it is unclear whether the observed OFC is universally cost-effective in all contexts vs gradually titrated home OFCs when caregivers are willing to accept a risk-to-benefit tradeoff.</div></div><div><h3>Objective</h3><div>To characterize the health and economic benefits of at-home vs supervised reintroduction OFC in patients with a history of mild-moderate index FPIES.</div></div><div><h3>Methods</h3><div>Cohort analyses evaluated the cost-effectiveness of a gradually titrated home vs clinical or hospital OFC using population simulations (n = 200,000 patients) and simulations in a rural New England population (n = 105). Severe FPIES reactions were defined as necessitating intravenous fluids. Fatality rates were defined as occurring approximately in 1/1,000,000 FPIES OFCs. Motor vehicle fatality rates were applied based on the travel distance to the OFC site. The cost-effectiveness threshold was set at $10,000,000 per fatality prevented.</div></div><div><h3>Results</h3><div>In the population simulation, the supervised OFC costs reached $411,088,445, with 18,680 severe reactions occurring (per-patient mean 0.093, SD 0.025), at a cost-per-fatality prevented of $124,233,328. In a simulation of a rural New England population with FPIES, the cost per severe reaction ranged from $11,790 to $46,304.</div></div><div><h3>Conclusion</h3><div>A requirement for universally conducting FPIES challenges in an office-based or in-hospital setting is not cost-effective given extremely low FPIES reaction fatality rates, especially when compared with travel-based motor vehicle fatality rates. A shared decision-making approach may be appropriate to determine the challenge setting for patients with lower risk of severe reactions.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 706-712.e2"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S1081-1206(25)00217-0","DOIUrl":"10.1016/S1081-1206(25)00217-0","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Page A1"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do not wait to challenge children","authors":"Grace Koo MD ,&nbsp;Anjali Sundar MD ,&nbsp;Kimberly B. Woodward APRN ,&nbsp;Cosby A. Stone Jr MD ,&nbsp;Allison E. Norton MD","doi":"10.1016/j.anai.2025.03.006","DOIUrl":"10.1016/j.anai.2025.03.006","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 736-738"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How we treat severe atopic dermatitis","authors":"Ellen Chinchilli BA ,&nbsp;Anna De Benedetto MD ,&nbsp;Lisa A. Beck MD","doi":"10.1016/j.anai.2025.03.005","DOIUrl":"10.1016/j.anai.2025.03.005","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 660-663"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantifying corticosteroid burden in chronic rhinosinusitis with nasal polyps","authors":"Joseph K. Han MD ,&nbsp;Jared Silver MD ,&nbsp;Indu Dhangar BDS ,&nbsp;Phani Veeranki MD, DrPH ,&nbsp;Arijita Deb PhD","doi":"10.1016/j.anai.2024.10.015","DOIUrl":"10.1016/j.anai.2024.10.015","url":null,"abstract":"<div><h3>Background</h3><div>Real-world burden data on systemic corticosteroid (SCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) are limited.</div></div><div><h3>Objective</h3><div>To describe the real-world burden of SCS in CRSwNP.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included commercial/Medicare Advantage with Part D health plan members from the Optum Research Database with a first medical claim (index) for CRSwNP (January 2015-July 2020). Primary outcomes/variables included SCS use, health care resource utilization, and costs during the 12-month follow-up period. Outcomes were analyzed overall (N = 21,172) and stratified by baseline comorbid asthma status and sinus surgeries during follow-up.</div></div><div><h3>Results</h3><div>Overall, 64.7% and 41.0% of patients used all-cause and CRSwNP-related SCS, respectively, and 36.0% had ≥1 oral corticosteroid (OCS) burst (≥20 mg for 3-28 days); SCS use was higher in patients with asthma and those with a NP-related surgery (1, 2, and ≥3) vs without. The mean (SD) all-cause cumulative oral corticosteroid dose was 303.3 (675.0) mg/year and 23.5% had a cumulative annual dose ≥400 mg; these values were higher (<em>P</em> &lt; .001) in patients with vs without comorbid asthma (514.9 [956.1] vs 247.5 [567.0]; 36.9% vs 19.9%). All-cause and CRSwNP health care resource utilization and costs increased with increasing number of surgeries; mean (SD) all-cause total medical costs were $14,472 (38,915), $26,909 (40,800), $29,816 (41,677), and $31,558 (37,143) with 0, 1, 2, and ≥3 surgeries, respectively.</div></div><div><h3>Conclusion</h3><div>These data highlight the significant burden of SCS use in CRSwNP, particularly in patients with comorbid asthma, and suggest a need to reduce SCS exposure.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 685-693.e5"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in real life","authors":"Robert Greig MBChB,&nbsp;Rory Chan PhD,&nbsp;Brian J. Lipworth MD","doi":"10.1016/j.anai.2025.03.013","DOIUrl":"10.1016/j.anai.2025.03.013","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 732-734"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR Bomb Squad","authors":"Erin L. Reigh MD, MS","doi":"10.1016/j.anai.2025.02.004","DOIUrl":"10.1016/j.anai.2025.02.004","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 658-659"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}